Brief: Invivo Therapeutics Announces 12-Month Data From Inspire Study

InVivo Therapeutics Holdings

28/08/2018 13:43

Aug 28 (Reuters) - InVivo Therapeutics Holdings Corp
 NVIV.O :
    * INVIVO THERAPEUTICS ANNOUNCES COMPLETE 12-MONTH DATA FROM
THE
INSPIRE STUDY OF THE INVESTIGATIONAL NEURO-SPINAL SCAFFOLD™ IN
ACUTE THORACIC COMPLETE SPINAL CORD INJURY
    * INVIVO THERAPEUTICS - ALL PATIENTS EVALUATED AT 12-MONTH
VISIT
WHO HAD CONVERTED AN AIS GRADE AT 6 MONTH VISIT REMAINED
CONVERTED AT 12 MONTH VISIT
    * INVIVO THERAPEUTICS - ONE PATIENT WAS LOST TO FOLLOW UP
AFTER
6-MONTH VISIT AND WAS NOT ASSESSED AT A 12-MONTH VISIT
    * INVIVO THERAPEUTICS HOLDINGS CORP - ALTOGETHER, 19
PATIENTS HAVE
BEEN IMPLANTED WITH NEURO-SPINAL SCAFFOLD IN INSPIRE STUDY

Source text for Eikon:  ID:nBw17FQgJa 
Further company coverage:  NVIV.O 

 ((Reuters.Briefs@thomsonreuters.com;))